LENSAR (NASDAQ:LNSR) Price Target Raised to $10.00

Key Points

• BTIG Research raised LENSAR’s price target to $10.00 from $9.00 and maintained a “buy” rating, implying 14.68% potential upside from the reported $8.72 share price.
• Analyst sentiment is mixed: two analysts rate the stock “buy,” one rates it “sell,” and MarketBeat’s overall consensus is “hold” with an average price target of $11.50.
• LENSAR reported quarterly EPS of $0.10, beating the consensus estimate of a $0.16 loss, while revenue of $16.50 million exceeded expectations of $14.65 million. Institutional investors own approximately 40.15% of the company.

LENSAR (NASDAQ:LNSR - Get Free Report) had its target price boosted by investment analysts at BTIG Research from $9.00 to $10.00 in a research report issued on Thursday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. BTIG Research's price objective would indicate a potential upside of 14.68% from the company's current price.

A number of other equities research analysts also recently issued reports on the company. Lake Street Capital restated a "buy" rating and set a $13.00 price objective on shares of LENSAR in a research report on Thursday, August 13th. Weiss Ratings reissued a "sell (d+)" rating on shares of LENSAR in a research report on Friday, August 7th. Finally, Wall Street Zen upgraded LENSAR from a "sell" rating to a "hold" rating in a report on Saturday, August 15th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, LENSAR currently has an average rating of "Hold" and an average price target of $11.50.

LENSAR Stock Up 6.5%

Shares of NASDAQ:LNSR opened at $8.72 on Thursday. The firm has a fifty day simple moving average of $6.05 and a two-hundred day simple moving average of $7.25. LENSAR has a 52 week low of $4.95 and a 52 week high of $12.96. The stock has a market capitalization of $107.17 million, a P/E ratio of -26.42 and a beta of 0.89.

LENSAR (NASDAQ:LNSR - Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.26. The firm had revenue of $16.50 million for the quarter, compared to analysts' expectations of $14.65 million. LENSAR had a net margin of 57.57% and a negative return on equity of 529.08%.

Institutional Trading of LENSAR

Several institutional investors have recently added to or reduced their stakes in LNSR. Brandes Investment Partners LP grew its stake in shares of LENSAR by 10.1% during the fourth quarter. Brandes Investment Partners LP now owns 856,216 shares of the company's stock valued at $9,958,000 after buying an additional 78,513 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of LENSAR by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 507,603 shares of the company's stock worth $6,269,000 after acquiring an additional 1,446 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of LENSAR by 103.9% during the 2nd quarter. Geode Capital Management LLC now owns 219,373 shares of the company's stock worth $2,890,000 after acquiring an additional 111,802 shares during the last quarter. Groupe la Francaise boosted its holdings in LENSAR by 16.2% during the 1st quarter. Groupe la Francaise now owns 213,537 shares of the company's stock valued at $1,273,000 after acquiring an additional 29,813 shares during the period. Finally, BlackRock Inc. purchased a new position in LENSAR during the 2nd quarter valued at $1,057,000. Institutional investors own 40.15% of the company's stock.

LENSAR Company Profile

LENSAR, Inc, headquartered in Orlando, Florida, is a medical technology company specializing in advanced laser systems for ophthalmic surgery. Its flagship product, the LENSAR Laser System, combines proprietary three-dimensional imaging with precision-guided femtosecond laser delivery to perform critical steps in cataract procedures, including capsulotomy creation, lens fragmentation and corneal incisions.

Founded in 2005, LENSAR has concentrated its research and development efforts on enhancing surgical accuracy and patient outcomes in cataract treatment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source